文献速递银屑病与炎症性皮肤病

古塞奇尤单抗持续治疗长达5年的安全性特征一致:来自中重度银屑病3期VOYAGE 1和VOYAGE 2试验的汇总分析

Consistent safety profile with up to 5 years of continuous treatment with guselkumab: Pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis.
PubMed 文献 · J Am Acad Dermatol · 2021-11-17

该汇总分析纳入VOYAGE 1和VOYAGE 2两项3期试验中接受古塞奇尤单抗治疗的中重度银屑病患者,随访至第264周,共7166患者年。古塞奇尤单抗治疗组(包括安慰剂交叉组n=1221和阿达木单抗交叉组n=500)的不良事件率为149/100患者年,严重不良事件率为5.01/100患者年,关注的不良事件率均较低,年际间有波动但无上升趋势。结论认为持续治疗5年安全性特征保持一致且良好。

要点

  • 1721例古塞奇尤单抗治疗患者中1349例(78.4%)持续治疗至第252周。
  • 不良事件率149/100患者年,严重不良事件率5.01/100患者年。
  • 严重感染率0.85/100患者年,非黑色素瘤皮肤癌率0.34/100患者年,其他恶性肿瘤率0.45/100患者年,主要不良心血管事件率0.29/100患者年。

核心结论

  • 持续古塞奇尤单抗治疗银屑病5年期间安全性特征保持一致且良好。

研究设计与样本

  • 汇总VOYAGE 1和VOYAGE 2两项3期随机试验数据,患者随机分配至古塞奇尤单抗组、安慰剂组(第16周交叉至古塞奇尤单抗)或阿达木单抗组。
  • 两项研究至第24周设计相同;VOYAGE 1评估持续古塞奇尤单抗治疗(阿达木单抗组第52周交叉至古塞奇尤单抗),VOYAGE 2评估随机撤药/再治疗(第28-76周)。
  • 开放标签古塞奇尤单抗治疗自VOYAGE 1第52周和VOYAGE 2第76周开始,持续至第252周;汇总安全性数据经暴露调整,分析古塞奇尤单抗组包括安慰剂交叉组(n=1221)和阿达木单抗交叉组(n=500),随访至第264周。

主要发现

  • 患者总随访7166患者年;1721例古塞奇尤单抗治疗患者中1349例(78.4%)持续治疗至第252周。
  • 不良事件率为149/100患者年,严重不良事件率为5.01/100患者年。
  • 关注的不良事件率较低:严重感染0.85/100患者年,非黑色素瘤皮肤癌0.34/100患者年,非黑色素瘤皮肤癌以外的恶性肿瘤0.45/100患者年,主要不良心血管事件0.29/100患者年。
  • 年际间变异性明显,但未观察到上升趋势。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 第52周后无法进行直接治疗比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Guselkumab effectively treats moderate-to-severe psoriasis. OBJECTIVE: To evaluate the cumulative safety experience of guselkumab using pooled data from the VOYAGE 1 and 2 studies through 5 years. METHODS: Patients were randomized to guselkumab, placebo with crossover to guselkumab at week 16, or adalimumab. The studies were identical through week 24. VOYAGE 1 evaluated continuous guselkumab treatment (adalimumab-crossover-to-guselkumab at week 52), while VOYAGE 2 assessed randomized withdrawal/retreatment (weeks 28-76). Open-label guselkumab treatment was administered starting at week 52 in VOYAGE 1 and week 76 in VOYAGE 2 and continued through week 252. Pooled safety data were adjusted by exposure and analyzed in the guselkumab groups, including placebo-crossover-to-guselkumab (n = 1221) and adalimumab-crossover-to-guselkumab (n = 500), through week 264. RESULTS: Patients were followed for a total of 7166 patient-years (PY). Overall, 1349 of 1721 guselkumab-treated patients (78.4%) continued treatment through week 252. The rates of adverse and serious adverse events were 149/100 PY and 5.01/100 PY, respectively. Rates of adverse events of interest were low: serious infections (0.85/100 PY), nonmelanoma skin cancer (0.34/100 PY), malignancies other than nonmelanoma skin cancer (0.45/100 PY), and major adverse cardiovascular events (0.29/100 PY). Year-to-year variability was evident, but no increasing trend was observed. LIMITATIONS: No direct treatment comparisons were possible after week 52. CONCLUSION: The safety profile remained consistent and favorable during 5 years of continuous guselkumab treatment of psoriasis.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Blauvelt A, Tsai TF, Langley RG, et al. Consistent safety profile with up to 5 years of continuous treatment with guselkumab: Pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis. J Am Acad Dermatol. 2021. PMID: 34798201. doi:10.1016/j.jaad.2021.11.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。